October 30th 2024
Marc J. Braunstein, MD, PhD, discusses VOD risk factors, management strategies, and prevention strategies in the post-HSCT hematologic malignancy setting.
April 23rd 2024
Marc J. Braunstein, MD, PhD, FACP, of NYU Grossman Long Island School of Medicine, discusses lessons learned with program building and medical education with hematologic cancers.
November 29th 2023
Marc J. Braunstein, MD, PhD, discusses the evolution of autologous stem cell transplantation and ongoing treatment needed to better determine when ASCT should be recommended for patients with multiple myeloma.
November 9th 2023
Marc J. Braunstein, MD, PhD, discusses the evolution of stem cell transplant eligibility criteria in patients with multiple myeloma and highlights unanswered questions about the role of autologous stem cell transplantation following quadruplet induction regimens in this population.
December 11th 2022
OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.
January 11th 2022
When treating cancers that are considered generally incurable, such as multiple myeloma, one of the paradigms in oncology is to deliver the most effective therapies upfront to maximize the chances of prolonging remission.
January 12th 2021
Marc J. Braunstein, MD, PhD, discusses the role of daratumumab in multiple myeloma.
January 7th 2021
Marc J. Braunstein, MD, PhD, discusses management strategies in multiple myeloma.
December 18th 2020
Marc J. Braunstein, MD, PhD, discusses the expanding treatment armamentarium in multiple myeloma.
November 17th 2020
In light of the recent approvals of combination anti-myeloma regimens containing monoclonal antibodies, as well as the robust pipeline of novel targeted agents likely to be approved in the next year, there is much optimism in the field of multiple myeloma.
July 7th 2020
Marc J. Braunstein, MD, PhD, discusses the utility of maintenance therapy in patients with multiple myeloma.
May 13th 2020
Marc J. Braunstein, MD, PhD, discusses updated results from the GRIFFIN trial in multiple myeloma.
May 12th 2020
May 9th 2020
Marc J. Braunstein, MD, PhD, discusses quadruplet therapies in multiple myeloma.
April 16th 2020
Marc J. Braunstein, MD, PhD, factors to consider when determining whether a patient with multiple myeloma is eligible for stem cell transplant.
April 3rd 2020
Marc J. Braunstein, MD, PhD, discusses transplant eligibility in multiple myeloma.
November 27th 2019
Marc J. Braunstein, MD, PhD, discusses challenges pertaining to the bone marrow microenvironment in multiple myeloma.
November 20th 2019
Marc J. Braunstein, MD, PhD, discusses the ultra–high-risk patient population in smoldering multiple myeloma.